We are investigating the fairness of the proposed sale of OptiNose, Inc. (Nasdaq: OPTN) (“OptiNose”) to Paratek Pharmaceuticals (“Paratek”) for $9.00 per share in cash, plus a contingent value right (“CVR”) worth $5.00 per share payable in the event that certain net revenue milestones are achieved by OptiNose’s flagship drug, XHANCE.
Notably, as detailed below, the sale price is below the price target for OptiNose of at least three Wall Street analysts even including the CVR (source: TipRanks).
Additionally, the sale price is well below OptiNose’ 52-week high of $25.80, and thus the deal appears highly opportunistic.
If you remain an OptiNose shareholder and question the fairness of the price, you may contact our firm to discuss your legal rights at no charge by completing and submitting the form below.
Why is there an investigation?
On March 20, 2025, after the markets closed, OptiNose announced that it had agreed to be sold to Paratek for $9.00 per share in cash, plus a CVR worth $5.00 per share payable in the event that certain net revenue milestones are achieved by OptiNose’s flagship drug, XHANCE.
Notably, the sale price is below the price target for OptiNose of at least three Wall Street analysts even including the CVR:
- Matthew Caufield of H.C. Wainwright ($18.00 per share target)
- Thomas Flaten of Lake Street ($17.00 per share target)
- David Amsellem of Piper Sandler ($15.00 per share target)
(source: TipRanks)
Additionally, the sale price is well below OptiNose’ 52-week high of $25.80, and thus the deal appears highly opportunistic.
“We are investigating whether the OptiNose Board of Directors acted in the best interests of OptiNose shareholders in approving the sale,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter. “This includes whether the price agreed upon is fair to OptiNose shareholders, as well as whether all material information regarding the transaction has been fully disclosed.”